Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 2,690 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal saline solution Clear all

Conditions: Prostate Cancer
Interventions: vaccine vehicle only, DC/LNCaP; Biological
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain
Interventions: Caldolor, Normal Saline; Drug · Other
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Mobile, Alabama • Little Rock, Arkansas • Arcadia, California + 2 more

Conditions: Periodontal Diseases
Interventions: Xylocaine 2 % with 1:100,000 epinephrine, Bupivicaine 0.5% with 1:200,000 epinephrine, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: IgA Nephropathy
Interventions: OMS721, Vehicle (D5W or saline); Biological · Other
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 34
States / cities: Florence, Alabama • Mesa, Arizona • Phoenix, Arizona + 29 more

Conditions: COPD Exacerbation
Interventions: Formoterol, Placebo; Drug · Other
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Iron Deficiency Anemia, Pregnancy
Interventions: Ferric derisomaltose, Ferrous sulfate; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Miami, Florida • Ann Arbor, Michigan + 4 more

Conditions: Alopecia, Androgenetic
Interventions: Puregraft System, Celution System, Kerastem Therapy, Liposuction; Device · Procedure
Lead sponsor: Kerastem Technologies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Los Angeles, California • Miami, Florida • Highland Park, New Jersey + 1 more

Conditions: Cystic Fibrosis
Interventions: Oral Aztreonam, Nasal Aztreonam, Nasal Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 7 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Cleft Palate
Interventions: Oral acetaminophen, Ofirmev®, Opioid only; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 5 Months to 5 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Urothelial Carcinoma, Bladder Cancer
Interventions: Placebo, Pembrolizumab; Other · Drug
Lead sponsor: Matthew Galsky; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 28
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 22 more

Conditions: Spinal Cord Injuries, Neurogenic Bladder
Interventions: Lactobacillus RhamnosusGG, Saline bladder wash; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Postoperative Pain
Interventions: Placebo, EXPAREL 67 mg, EXPAREL 133 mg, EXPAREL 266 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 30
States / cities: Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 23 more

Conditions: Neuroblastoma, Pheochromocytoma, Paraganglioma
Interventions: I-131 MIBG, Vorinostat; Radiation · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Months and older
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hereditary Hemochromatosis
Interventions: LJPC-401, Placebo; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 18
States / cities: North Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 15 more

Conditions: COVID-19
Interventions: Convalescent Plasma, Masked Saline Placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 20 more

Conditions: Pelvic Organ Prolapse, Surgery, Postoperative Pain
Interventions: Dexamethasone, Bupivacaine, Bilateral Pudendal Nerve Block, Bilateral Levator Ani Muscle Injection, Saline; Drug · Procedure
Lead sponsor: Lauren Giugale, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: AL Amyloidosis
Interventions: CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Stanford, California • Detroit, Michigan • Cleveland, Ohio

Conditions: GBS Disease, Streptococcus Agalactiae
Interventions: GBS trivalent vaccine, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Aurora, Colorado • Baltimore, Maryland • Durham, North Carolina + 3 more

Conditions: Gastroenteritis, Dehydration
Interventions: 5% dextrose in normal saline; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Months to 6 Years
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Somatostatin, Dextrose, Insulin, Intralipid; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pain
Interventions: Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min, Placebo Comparator: .9 normal saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Abdominal Trauma
Interventions: Focused Assessment with Sonography for Trauma (FAST), Bubble-Enhanced FAST (BEFAST); Diagnostic Test · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypertension
Interventions: Nesiritide (BNP), Placebo; Drug
Lead sponsor: John C Burnett; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Shock, Septic
Interventions: Lactated Ringer, Normal Saline, Plasma-lyte; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Months to 17 Years
Enrollment: 9,041 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 22
States / cities: Davis, California • Los Angeles, California • San Francisco, California + 19 more

Search by objective public record fields.

Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.

Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients

Immediate Post-Operative Anesthesia With Either Lidocaine or Bupivacaine

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia

Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease

Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

Intravesical LGG VS Saline Bladder Wash RCT

Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

VA CoronavirUs Research and Efficacy Studies-1

Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women

Study Investigating the Use of Intravenous Fluids With Dextrose for Dehydrated Children

Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion

The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery

BEFAST (Bubble-Enhanced FAST) for the Evaluation of Solid Organ Injury

Nesiritide in Resistant Hypertension

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis